Anbenitamab in combination with chemotherapy in patients with HER2‐positive gastric or gastroesophageal junction carcinoma who failed previous therapy containing trastuzumab: a multicenter, phase II study (KC‐WISE 01)

Ítems similars

• Targeted and Immunotherapy Approaches in HER2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma: A New Era
  per: Maluki Radford, et al.
  Publicat: (2023-08-01)
• Case report: Chemotherapy plus sintilimab for the treatment of gastroesophageal junction hepatoid adenocarcinoma with liver metastasis: a case study with literature review
  per: Genlin Lu, et al.
  Publicat: (2025-01-01)
• Cost-effectiveness analysis of first-line sintilimab plus chemotherapy vs. chemotherapy alone for unresectable advanced or metastatic gastric or gastroesophageal junction cancer in China
  per: Zuojuan Xiang, et al.
  Publicat: (2024-09-01)
• Real-world treatment patterns and outcomes in advanced/metastatic gastric cancer or gastroesophageal junction adenocarcinoma treated with first-line anti-HER2 therapy in England
  per: N. Starling, et al.
  Publicat: (2025-12-01)
• Kyoto International Consensus Report on Anatomy, Pathophysiology and Clinical Significance of the Gastroesophageal Junction
  per: A. A. Sheptulin, et al.
  Publicat: (2023-12-01)